COMP <GO>
GYRE vs UNH // 10Y YIELD & FRED MACRO BETA
Gyre Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: GYRE 6
— UNH 7
■ METRIC PARITY
LAST: $6.41 (-9.59%) • MKT CAP: $714.8M
macro-sensitivity
—
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
macro-sensitivity
0.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GYRE VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GYRE | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 95.40% | 88.57% | +6.83 | GYRE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 25.40% | 11.47% | +13.93 | GYRE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 53.3x | 16.4x | +36.85 | UNH | /valuation <GO> |
| Free Cash Flow Yield | -0.03% | 6.48% | -6.51 | UNH | /fcf-yield <GO> |
| Operating Margin | 9.90% | 4.82% | +5.08 | GYRE | /operating-margins <GO> |
| Net Profit Margin | 8.50% | 3.14% | +5.36 | GYRE | /net-margins <GO> |
| Revenue Growth (YoY) | 10.20% | 6.46% | +3.74 | GYRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.33 | 3.12 | +11.21 | GYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 59.2 | -9.40 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 67.2x | 17.7x | +49.46 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $714.8M | $368.83B | -$368.12B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GYRE REV | UNH REV | GYRE GROSS % | UNH GROSS % | GYRE FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $116.6M | $447.57B | 95.4% | 88.7% | -$180.0K | $16.07B |
| FY 2024 | $105.8M | $400.28B | 96.3% | 88.3% | -$6.0M | $20.70B |
| FY 2023 | $113.5M | $371.62B | — | 89.6% | $25.9M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GYRE // BETA —
UNH // BETA 0.33